Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
NCT ID: NCT02956967
Last Updated: 2019-02-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
171 participants
OBSERVATIONAL
2015-09-23
2016-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
NCT02178475
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
NCT01813721
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
NCT03104595
Various G-CSF Regimens to Prevent Infection During Chemotherapy
NCT00536081
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
NCT00883181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients receiving Nivestim
Overall satisfaction questionnaires of home use of Nivestim
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Overall satisfaction questionnaires of home use of Nivestim
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Declaration of informed consent signed by patient
* Patients with a solid tumour or with a malignant haematological tumour
* Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle
* GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment
* Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN
Exclusion Criteria
* Patients who are hypersensitive to one of the excipients of NivestimTM
* Patients not undergoing chemotherapy
* Patients being treated curatively or as secondary prophylaxis with G-CSF
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Office of Manfred Welslau
Aschaffenburg, , Germany
Office of Martine Klausmann
Aschaffenburg, , Germany
Office of Bernhard Heinrich
Augsburg, , Germany
Campus Charite Mitte, Med. Klinik m. Schwerpunkt Haematologie und Onkologie
Berlin, , Germany
Office of Reinhard Musch
Berlin, , Germany
Office of Peter Klare
Berlin, , Germany
Office of Ute Bückner
Bochum, , Germany
Office of Peter Jungberg
Chemnitz, , Germany
Office of Ivo Azeh
Gelsenkirchen, , Germany
Office of Peter von Wussow
Hanover, , Germany
Office of Volker Petersen
Heidenheim, , Germany
Office of Lars-Jörgen Hahn
Herne, , Germany
Office of Michael Neise
Krefeld, , Germany
Office of Gunther Rogmans
Krefeld, , Germany
Office of Peter Anhut
Kronach, , Germany
Office of Albrecht Kretzschmar
Leipzig, , Germany
Office of Nidal Gazawi
Leipzig, , Germany
Office of Udo Hieber
Mannheim, , Germany
Office of Christoph Salat
München, , Germany
Office of Christian Lerchenmüller
Münster, , Germany
Office of Burkhard Otremba
Oldenburg, , Germany
Office of Julian Topaly
Osnabrück, , Germany
Office of Andre-Robert Rotmann
Rodgau, , Germany
Office of Rene Schubert
Scheibenberg, , Germany
Office of Matthias Groschek
Stolberg, , Germany
Office of Carsten Hielscher
Stralsund, , Germany
Office of Thomas Kuhn
Stuttgart, , Germany
Office of Ortwin Klein
Wiesbaden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Otremba B, Hielscher C, Petersen V, Petrik C. Home administration of filgrastim (Nivestim) in primary prophylaxis of chemotherapy-induced febrile neutropenia. Patient Prefer Adherence. 2018 Oct 16;12:2179-2186. doi: 10.2147/PPA.S168029. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1121004
Identifier Type: OTHER
Identifier Source: secondary_id
ZOB-NIV-1504
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.